Transferred herpes simplex virus immunity after stem-cell transplantation: Clinical implications
Transferred herpes simplex virus immunity after stem-cell transplantation: Clinical implications
复制标题
DOI：
10.1086/367894
复制
发表时间：
2003-03-01
影响因子：
6.4
通讯作者：
Corey, L
中科院分区：
文献类型：
--
作者：
Nichols, WG;Boeckh, M;Corey, L
尽管进行了阿昔洛韦预防，单纯疱疹病毒（HSV）通常在干细胞移植（SCT）后重新激活。研究人员探讨了与 HSV 血清阴性或类型不一致的供者相比，HSV 血清阳性受者与 HSV 血清阴性或类型不一致的供者相比，HSV 感染是否更频繁和更严重。对 HSV 阳性 SCT 受者及其捐赠者的储存血清样本进行了检测，以确定是否存在 HSV 抗体。来自 HSV-1 阴性供者的 HSV-1 阳性 SCT 受者比来自 HSV-1 阳性供者的 HSV-1 阳性 SCT 受者的发作频率更高、时间更长；随访天数超过 10% 的患者接受抗病毒治疗的比例分别为 27.4% 和 7.2%（P
Herpes simplex virus (HSV) commonly reactivates after stem-cell transplantation (SCT), despite acyclovir prophylaxis. Whether HSV-seropositive recipients with HSV-seronegative or type-discordant donors had more frequent and severe HSV infections than those with HSV type-concordant donors was explored. Banked serum samples from HSV-positive SCT recipients and their donors were tested for the presence of HSV antibodies. HSV-1-positive SCT recipients from HSV-1-negative donors had more frequent and longer episodes than HSV-1-positive SCT recipients from HSV-1-positive donors; the proportion of patients receiving antiviral treatment for >10% of follow-up days was 27.4% versus 7.2% (P